3 Reasons Why Growth Investors Shouldn't Overlook LeMaitre (LMAT)
LeMaitre (LMAT) is well positioned to outperform the market, as it exhibits above-average growth in financials.
LeMaitre Vascular (LMAT) Q3 Earnings Surpass Estimates
LeMaitre Vascular (LMAT) came out with quarterly earnings of $0.62 per share, beating the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.49 per share a year ago.
LeMaitre (LMAT) is an Incredible Growth Stock: 3 Reasons Why
LeMaitre (LMAT) is well positioned to outperform the market, as it exhibits above-average growth in financials.
LeMaitre Vascular, Inc. (LMAT) Q2 2025 Earnings Call Transcript
LeMaitre Vascular, Inc. (NASDAQ:LMAT ) Q2 2025 Earnings Conference Call August 5, 2025 5:00 PM ET Company Participants David B. Roberts - President & Director Dorian LeBlanc - Chief Financial Officer George W.
LeMaitre Vascular (LMAT) Beats Q2 Earnings and Revenue Estimates
LeMaitre Vascular (LMAT) came out with quarterly earnings of $0.6 per share, beating the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.52 per share a year ago.
LeMaitre Vascular, Inc. (LMAT) Q1 2025 Earnings Call Transcript
LeMaitre Vascular, Inc. (LMAT) Q1 2025 Earnings Call Transcript
LeMaitre Vascular (LMAT) Lags Q1 Earnings Estimates
LeMaitre Vascular (LMAT) came out with quarterly earnings of $0.48 per share, missing the Zacks Consensus Estimate of $0.50 per share. This compares to earnings of $0.44 per share a year ago.
LeMaitre (LMAT) Soars 7.7%: Is Further Upside Left in the Stock?
LeMaitre (LMAT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
3 Reasons Growth Investors Will Love LeMaitre (LMAT)
LeMaitre (LMAT) could produce exceptional returns because of its solid growth attributes.
Best Momentum Stocks to Buy for March 4th
OPCH and LMAT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 4, 2025.
LeMaitre (LMAT) Upgraded to Buy: Here's What You Should Know
LeMaitre (LMAT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
LeMaitre Vascular, Inc. (LMAT) Q4 2024 Earnings Call Transcript
LeMaitre Vascular, Inc. (NASDAQ:LMAT ) Q4 2024 Earnings Conference Call February 27, 2025 5:00 PM ET Company Participants J.J. Pellegrino - Chief Financial Officer George LeMaitre - Chief Executive Officer Dave Roberts - President Conference Call Participants Nathan Treybeck - Wells Fargo Danny Stauder - Citizens JMP Matthew Park - Cantor Fitzgerald Frank Takkinen - Lake Street Capital Markets Michael Petusky - Barrington Research Jim Sidoti - Sidoti & Company Operator Welcome to the LeMaitre Vascular Q4 2024 Financial Results Conference Call.
